Accella Advisors


Project: Turnaround Management

       The problem
An Austrian biotech company with an innovative mechanism of action had problems rounding out the syndicate for their first financing round and ran into liquidity problems. The lead investor asked for support.

The solution
The business plan and company presentation were restructured to sharpen the company profile. Management of the fundraising was taken over. It was proposed to investors to manage the company in a very capital efficient manner with a lean organization and a project focussed operational plan.

The outcome
A syndicate of renowned international venture funds invested into the company, resulting in one of the largest series A financings in Europe in recent years. After successful fundraising, the CEO function was assumed by one of Accella Advisor's partners. The company was built out to enable detailed understanding of the company's compounds and organize a very significant and successful clinical proof of concept study. In addition the scope of potential clinical application was broadened significantly and new lead compounds were discovered.
As a result the company was recently able to enter into a very significant license agreement with a leading US biotech company who will take several of the company's products forward towards registration.
Accella Advisors will continue to work with the licensee to ensure flawless execution of the agreed upon development plans.